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Background-—Previous studies have provided conﬂicting results as to whether women are at higher risk than men for
thromboembolism in the setting of atrial ﬁbrillation (AF). We investigated whether women with AF were at higher risk of ischemic
stroke in the China-AF (China Atrial Fibrillation Registry) Study.
Methods and Results-—A total of 19 515 patients were prospectively enrolled between August 2011 and December 2016 in the
China-AF Study. After exclusion of patients receiving anticoagulation or ablation therapy, 6239 patients (2574 women) with results
from at least 6 months of follow-up were used for the analysis. Cox proportional hazards models were performed to evaluate
whether female sex was an independent risk factor for thromboembolism after multivariate adjustment. The primary outcome was
the time to the ﬁrst occurrence of ischemic stroke or systemic embolism. After a mean follow-up of 2.811.46 years, 152 female
patients reached the primary outcome, as compared with 172 male patients. Crude incidence rates of thromboembolism between
women and men were of borderline statistical signiﬁcance (2.08 versus 1.68 per 100 patient-years, P=0.058). After multivariable
analysis, female sex was not independently associated with an increased thromboembolism risk (hazard ratio 1.09, 95% conﬁdence
interval 0.86-1.39). There was no signiﬁcant difference in thromboembolism risk by sex stratiﬁed by age and presence or absence
of risk factors (P for interaction all >0.1).
Conclusions-—Although crude incidence rates of thromboembolism were higher in Chinese female patients with AF compared with
male patients, female sex did not emerge as an independent risk factor for thromboembolism on multivariate analysis.
Clinical Trial Registration-—URL: http://www.chictr.org.cn/. Unique identiﬁer: ChiCTR-OCH-13003729. ( J Am Heart Assoc.
2018;7:e009391. DOI: 10.1161/JAHA.118.009391.)
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A trial ﬁbrillation (AF) is the most common sustainedarrhythmia and is associated with a 5-fold increase in
the risk of ischemic stroke.1 Usually, female AF patients tend
to be older, with more comorbidities, and therefore to have a
higher incidence of stroke.2,3 However, whether female sex is
a prognostic factor for stroke is still uncertain. Large-cohort
studies have indicated that women with AF are at 10% to 90%
higher risk of stroke than men,2,4-8 whereas others failed to
ﬁnd such an association.9-12 Notably, the ATRIA (Anticoagu-
lation and Risk Factors in Atrial Fibrillation) study indicated
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that women were at 60% and 80% increased stroke risk than
men for those aged ≤75 and >75 years respectively,4
whereas 3 other studies have reported that female sex is
associated with 10% to 23% higher risk of stroke only for
patients over the age of 75.6-8 Furthermore, the Danish
nationwide cohort study suggested that the excess stroke risk
for women was evident among those with ≥2 non–sex-related
risk factors.13 Conversely, a recent Korean nationwide cohort
study showed that female patients had a lower risk of
ischemic stroke than males.14 Hence, contemporary European
and American AF guidelines are inconsistent in their recom-
mendations as to whether female sex should be used as a risk
factor in deciding anticoagulation therapy.15,16
In this study we used data from the China-AF (China Atrial
Fibrillation Registry) cohort to evaluate whether women are at
higher risk for stroke or systemic embolism (SE) after
adjustment of other confounding factors and whether the
association is consistent among different subgroups.
Methods
For the concern about intellectual property and patient
privacy, the data, analytic methods, and study materials of
this study will not be made available to other researchers for
purposes of reproducing the results or replicating the
procedure.
Study Population
The China-AF study is a prospective, multicenter, hospital-
based, ongoing registry study of patients diagnosed with AF.
The main purpose of this observational study is to understand
the current clinical practice patterns, prognoses, and related
factors in Chinese AF patients and to compare different
treatments in real-world practice. Details of the cohort have
been described previously.17 Ethics approval was obtained
from the local institutional review board, and written informed
consent was obtained from patients. From August 2011 to
December 2016, 19 515 AF patients were recruited from
outpatient clinics and in-hospital patients of 31 hospitals
located in Beijing, China. Patients were followed up at
3 months, 6 months, and every 6 months thereafter. In this
analysis we excluded patients with a follow-up of less than
6 months (n=3316) and patients with mitral stenosis or
valvular repair or replacement (n=464). Patients receiving oral
anticoagulant treatment at baseline (n=3225) were excluded,
andwe also excluded patients who underwent catheter ablation
(n=6271) to exclude any possible impact of the procedure on
stroke risk.18-20 Finally, 6239 participants were included in this
analysis. A ﬂowchart of the study is shown in Figure 1.
Information on patient characteristics, including age, sex,
lifestyle factors, type of AF, medical history, medication,
education, and insurance, was collected when patients were
enrolled. Deﬁnitions of each variable were in line with the
American College of Cardiology/American Heart Association
recommendation on AF clinical data standards and interna-
tional peer studies.21
Follow-Up
Each enrolled patient was followed up at outpatient clinic or
through telephone interview every 6 months. Information of
medical or interventional therapies, events of incident
ischemic stroke/SE, bleedings, hospitalizations, and deaths
was collected at each follow-up occasion. Person-time was
Figure 1. Flowchart of patients included. AF indicates atrial
ﬁbrillation; NVAF, nonvalvular atrial ﬁbrillation.
Clinical Perspective
What Is New?
• Our study showed that female sex did not emerge as an
independent risk factor for stroke and systemic embolism in
Chinese atrial ﬁbrillation patients.
• No signiﬁcant interactions between sex and age or comor-
bidities was found for thromboembolism.
What Are the Clinical Implications?
• Our ﬁndings do not support consideration of oral anticoag-
ulant treatment for female Chinese patients with a
CHA2DS2-VASc score of 1.
• Initial decisions on oral anticoagulant treatment guided by a
CHA2DS2-VA approach (ie, ignoring the Sex category [Sc]
criterion) may be appropriate.
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censored at the time the patient initiated oral anticoagulant
therapy, catheter ablation was applied, ﬁrst ischemic stroke/
SE or death occurred, or the time data were analyzed.
Ascertainment of Thromboembolic Events
The primary outcome was the time to the ﬁrst occurrence of a
thromboembolic event, including ischemic stroke and SE,
whichever came ﬁrst. Patient-reported nonfatal thromboem-
bolic events were adjudicated by 2 independent neurologists
separately. Disagreement was resolved by discussion or by
involving other senior neurologists.
Deﬁnitions
The estimated glomerular ﬁltration rate based on creatinine
was calculated with the modiﬁed equation for Chinese patients
with chronic kidney disease.22 The CHADS2 score was
calculated for each patient by giving 1 point to each patient
of age ≥75 years, history of hypertension, diabetes mellitus,
and congestive heart failure and 2 points to each patient with a
history of thromboembolism.23 We also calculated the
CHA2DS2-VASc score by giving 2 points to each patient of
age ≥75 years and a history of thromboembolism and 1 point to
each patient of age 65 to 74 years, history of hypertension,
diabetes mellitus, congestive heart failure, vascular disease,
and female sex.24 A sexless CHA2DS2-VASc score (ie, removing
female sex), abbreviated as CHA2DS2-VA, was calculated by
excluding female sex from CHA2DS2-VASc score.
Statistical Analyses
Descriptive statistics were used to compare demographic
characteristics, comorbid conditions, and concomitant medi-
cation between men and women. Continuous variables were
presented as mean and standard deviation or median and
interquartile range as appropriate. A t test or theWilcoxon rank-
sum test was used to compare the differences. Dichotomous
variables were presented as percentages and were compared
by v2 test. Incidence rate of thromboembolic events was
reported as the number of events per 100 person-years of
follow-up in women and men, respectively. Cumulative inci-
dence rates were estimated with the Kaplan-Meier method and
compared with the log-rank test by sex and age groups.
Cox proportional hazards regression was employed to
estimate the association between sex and stroke in a series
of models with incremental adjustments as follows: model 1
was adjusted for age as a continuous variable; model 2 was
adjusted for age, congestive heart failure, hypertension,
diabetes mellitus, thromboembolism, and vascular disease;
and model 3 was adjusted for all covariates with P<0.2 in the
univariate Cox regression model. Results are expressed as
hazard ratios with their 95% conﬁdence intervals (CIs).
Interactions between selected variables and sex were tested
after multiple adjustment and presented in a forest plot. If
covariate data were missing for the Cox regression models,
PROC MIANALYZE was used, with a multiple imputation
method, to calculate hazard ratios and their 95% CIs and to
conduct valid statistical inferences from 5 imputed data sets.
All statistical analyses were performed using SAS version
9.4 (SAS Institute, Cary, NC). All statistical tests were 2-sided;
a P<0.05 was considered statistically signiﬁcant.
Results
We included 2574 women and 3665 men with AF in this
analysis: of these, 2576 (41.29%) were identiﬁed during
hospitalization, 3500 (56.10%) were enrolled from outpatient
clinics, and 163 (2.61%) were enrolled from the emergency
department. Baseline characteristics of male and female
patients were shown in Table 1. Women were generally older
(mean age 70.2 years versus 65.8 years, P<0.0001) and were
more likely to have a history of heart failure, hypertension, or
diabetes mellitus but were less likely to have diagnosed
vascular disease than men. Women had higher mean CHADS2
(2.0 versus 1.7, P<0.0001) and CHA2DS2-VASc (3.9 versus
2.4, P<0.0001) scores.
Thromboembolic Events
During a mean follow-up of 2.811.46 years, 324 thromboem-
bolic events (291 ischemic strokes and 33 systemic embolisms)
occurred.Womenaccrued152 thromboembolic events,whereas
men accumulated 172 events, with corresponding incidence
rates of 2.08 and 1.68 per 100 patient-years, respectively.
Crude incidence rates of thromboembolism betweenwomen and
men were of borderline statistical signiﬁcance (P=0.058).
Cumulative incidence rates of ischemic stroke/SE subdi-
vided by sex and age groups (<65, 65-74, and ≥75 years) are
shown in Figure 2. On Kaplan-Meier analysis, women were at
not at higher risk of stroke/SE than similar-aged men across
different age groups.
Women had nonsigniﬁcantly different incidences of throm-
boembolism than men for each CHA2DS2-VA score group
(Figure 3). The absolute risk of thromboembolism was low
among patients with a CHA2DS2-VA score of 0, being 0.61,
0.29 per 100 patient-year for women and men (P=0.286),
respectively.
Multivariate Analysis
After age had been adjusted as a continuous variable, female
sex was still nonsigniﬁcantly associated with thromboembolic
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Table 1. Baseline Characteristics by Sex
Characteristics Whole Cohort (N=6239) Men (N=3665) Women (N=2574) P Value
Age, y 67.612.6 65.813.4 70.210.8 <0.0001
BMI, kg/m2 25.13.6 25.23.5 25.03.8 0.1324
SBP, mm Hg 129.717.8 128.616.9 131.318.8 <0.0001
Pulse pressure, mm Hg 51.915.3 50.214.6 54.215.9 <0.0001
Heart rate, bpm 81.721.9 80.820.9 82.923.2 0.0003
eGFR <60, mL/(min/1.73 m2) 347/4615 (7.5) 136/2640 (5.2) 211/1975 (10.7) <0.0001
Echocardiography
Anteroposterior left atrial
diameter, mm
40.68.1 41.07.9 40.08.4 <0.0001
Moderate to severe
mitral regurgitation
294/4488 (6.6) 160/2618 (6.1) 134/1870 (7.2) 0.1593
Smoking
Current 974/6198 (15.7) 903/3639 (24.8) 71/2559 (2.8) <0.0001
Former 1056/6198 (17.0) 963/3639 (26.5) 93/2559 (3.6)
Never 4168/6198 (67.2) 1773/3639 (48.7) 2395/2559 (93.6)
Alcohol use
Current 1101/6193 (17.8) 1063/3635 (29.2) 38/2558 (1.5) <0.0001
Former 718/6193 (11.6) 692/3635 (19.0) 26/2558 (1.0)
Never 4374/6193 (70.6) 1880/3635 (51.7) 2494/2558 (97.5)
AF type
Newly diagnosed 852/6236 (13.7) 457/3664 (12.5) 395/2572 (15.4) 0.0006
Paroxysmal 3297/6236 (52.9) 1928/3664 (52.6) 1369/2572 (53.2)
Persistent 2087/6236 (33.5) 1279/3664 (34.9) 808/2572 (31.4)
Medical history
Congestive heart failure 1492/6239 (23.9) 768/3665 (21) 724/2574 (28.1) <0.0001
Hypertension 4177/6239 (66.9) 2278/3665 (62.2) 1899/2574 (73.8) <0.0001
Diabetes mellitus 1618/6239 (25.9) 845/3665 (23.1) 773/2574 (30.0) <0.0001
Thromboembolism 1027/6238 (16.5) 582/3664 (15.9) 445/2574 (17.3) 0.1410
Ischemic stroke 891/6238 (14.3) 505/3664 (13.8) 386/2574 (15.0) 0.1775
Vascular disease 1390/6238 (22.3) 868/3664 (23.7) 522/2574 (20.3) 0.0014
Previous bleeding 325/6237 (5.2) 199/3663 (5.4) 126/2574 (4.9) 0.3470
Hyperlipidemia 1875/6217 (30.2) 979/3652 (26.8) 896/2565 (34.9) <0.0001
Hypertrophic cardiomyopathy 50/6226 (0.8) 26/3657 (0.7) 24/2569 (0.9) 0.3312
Dilated cardiomyopathy 53/6238 (0.8) 41/3664 (1.1) 12/2574 (0.5) 0.0057
Stroke risk score
CHADS2 1.81.5 1.71.5 2.01.5 <0.0001
CHA2DS2-VASc 3.02.0 2.41.9 3.91.9 <0.0001
Concomitant medication
Antiplatelet 1674/6239 (26.8) 1010/3665 (27.6) 664/2574 (25.8) 0.1221
Statins 2596/6239 (41.6) 1437/3665 (39.2) 1159/2574 (45.0) <0.0001
ACEIs/ARBs 2545/6238 (40.8) 1381/3664 (37.7) 1164/2574 (45.2) <0.0001
Completed high school 1615/5496 (29.4) 1185/3252 (36.4) 430/2244 (19.2) <0.0001
Continued
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risk (hazard ratio 1.06, 95% CI 0.85-1.32, Table 2). The
association remained nonsigniﬁcant (hazard ratio 1.02, 95% CI
0.82-1.27) even after adjustment for age, history of congestive
heart failure, hypertension, diabetes mellitus, thromboem-
bolism, and vascular disease. The results were similar (hazard
ratio 1.09, 95% CI 0.86-1.39) when all covariates with P<0.2 in
univariate cox regression model (including age, estimated
glomerular ﬁltration rate, left atrial diameter, moderate-to-
severe mitral regurgitation, history of congestive heart failure,
hypertension, diabetes mellitus, thromboembolism, vascular
disease, previous bleeding, use of angiotensin-converting
enzyme inhibitor and/or angiotensin II receptor blocker, and
Table 1. Continued
Characteristics Whole Cohort (N=6239) Men (N=3665) Women (N=2574) P Value
Health insurance coverage
100% 795/6239 (12.7) 517/3665 (14.1) 278/2574 (10.8) 0.0006
Partially 4944/6239 (79.2) 2857/3665 (78.0) 2087/2574 (81.1)
None 500/6239 (8.0) 291/3665 (7.9) 209/2574 (8.1)
Data are shown as meanSD or n/N (%). History of thromboembolism includes ischemic stroke, transient ischemic attack and systemic embolism. Alcohol use is deﬁned as at least 20 g
of pure alcohol on 1 occasion for both men and women. Previous bleeding means clinically relevant major or nonmajor bleeding. ACEIs indicates angiotensin-converting enzyme inhibitors;
AF, atrial ﬁbrillation; ARBs, angiotensin II receptor blockers; BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; SBP, systolic blood pressure.
Figure 2. Cumulative incidence rates of ischemic stroke/SE in women and men, stratiﬁed by age groups.
*Comparisons between men and women, by Log-rank test. SE indicates systemic embolism.
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completion of high school) were adjusted. Table S1 provides all
risk estimates of the different covariates included in the
univariate and multivariate Cox regression model.
Subgroup Analysis
In subgroups of different age groups (<65, 65-74, and
≥75 years), with and without history of heart failure, hyper-
tension, diabetes mellitus, thromboembolism, as well as
vascular diseases, with CHA2DS2-VA score ≤1 or ≥2, we found
no signiﬁcant interactions between sex and clinically relevant
variables (Figure 4).
Discussion
In this large cohort of Chinese patients with AF, we found that
although crude annual incidence rates of thromboembolism
were higher in Chinese female patients with AF compared with
male patients, female sex did not emerge as an independent
risk factor for stroke and systemic embolism on multivariate
analysis. In addition, no signiﬁcant interactions between sex
and age or comorbidities were found for thromboembolism.
The debate as to whether female sex is an independent
risk factor for thromboembolic events in patients with AF
remains. The earlier Framingham and ATRIA studies initially
reported female sex as a risk factor for stroke.4,5 However,
these cohorts were conducted in the era of a relatively low
awareness of AF and less optimal management of the
arrhythmia and associated risk factors. The recognition of
AF as a signiﬁcant clinical condition and improvements in
treatment of comorbidities may have contributed to the
elimination of sex differences in stroke.
Three more recent large-cohort studies in Canada, Sweden,
and Denmark suggested that there was a signiﬁcant interac-
tion between age and sex for the risk of stroke. Female sex
Figure 3. Crude incidence rates of ischemic stroke/SE per 100 person-years by sex according to
CHA2DS2-VA score. *Comparison between men and women by Fisher exact test. SE indicates systemic
embolism.
Table 2. Association Between Female Sex and Incidence of
Stroke/SE
Men Women
Hazard ratio (unadjusted) Reference 1.24 (0.99-1.54)
Hazard ratio (adjusted for age*) Reference 1.06 (0.85-1.32)
Hazard ratio (adjusted for age*,
history of heart failure, hypertension,
diabetes mellitus, thromboembolism,
vascular disease)
Reference 1.02 (0.82-1.27)
Hazard ratio (adjusted for variables
with P<0.2 in univariate
Cox regression models)
Reference 1.09 (0.86-1.39)
*Age considered as a continuous variable. SE indicates systemic embolism.
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was a risk factor for stoke only in patients aged ≥75 years,
not in those aged <75 years.6-8 However, the Canadian
cohort revisited their data recently and found no signiﬁcant
association between female sex and risk of thromboembolism
in patients older or younger than 75 years after matching on
age and using time-dependent adjustment for confounders.9
In addition, the Danish cohort also reviewed their data from 3
nationwide registries recently and showed that female sex
had signiﬁcant interaction with other risk factors and could be
considered a risk modiﬁer rather than a risk factor for stroke
in patients with AF.13 Other analyses based on the UK General
Practice Research Database and Asian cohort studies also
found no sex differences in stroke risk.10,11,14,25,26
Of note, none of the registry-based studies collected infor-
mation about lifestyle factors such as smoking, alcohol, and
obesity, whichmay affect the risk of thromboembolic events.27-29
The Danish Diet, Cancer and Health study suggested no sex
difference in stroke risk after controlling for lifestyle-related
factors, including smoking, alcohol, obesity, and hormone
replacement therapy.12 All of these ﬁndings suggest that
possible unadjusted confounders may contribute to the
observed association between female sex and risk of stroke.
In our study additional adjustment for echocardiographic,
lifestyle, and socioeconomic factors did not alter the associ-
ation between female sex and stroke risk.
Our study indicates that female sex is not an independent
risk factor for stroke in Chinese AF subjects and should not
necessarily be incorporated into their risk stratiﬁcation for
guiding anticoagulation therapy decisions. Current European
AF treatment recommendations are the same for female and
male patients based on additional risk factors beyond sex.15
In contrast, American guidelines still provide the possibility of
initiating anticoagulation based on female sex alone.16
However, our ﬁndings do not support consideration of oral
anticoagulant treatment for female Chinese patients with a
CHA2DS2-VASc score of 1, given that these patients displayed
an absolute risk of thromboembolism of 0.61 per 100 patient-
years.
Contemporary Canadian and Japanese AF guidelines also
do not include female sex as a risk factor in considering
anticoagulation treatment.30,31 Indeed, an analysis from the J-
RHYTHM Registry indicated that the CHA2DS2-VA score, a
risk-scoring system that excludes female sex from CHA2DS2-
VASc and performs better in risk stratiﬁcation for throm-
boembolic events than the CHA2DS2-VASc score, especially in
identifying truly low-risk Japanese AF patients.32 Nonetheless,
Figure 4. Risk of ischemic stroke/SE in women compared with men in clinically relevant subgroups. All interactions modeled within the
previous multivariable Cox regression, except CHA2DS2-VA score (in which only sex and CHA2DS2-VA score were included in the model). SE
indicates systemic embolism.
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the J-RHYTHM registry recorded anticoagulation use only at
baseline, and events at follow-up may be confounded by
anticoagulation use among high-risk subjects.
Although our ﬁndings suggest that female AF patients are
not exposed to extra risk of thromboembolic events, it is
important to realize that AF was more commonly detected at
ﬁrst stroke in women and was associated with worse stroke
outcomes.33 Women with AF are more likely to be under-
diagnosed and managed conservatively. It is reported that
women with AF are less likely to receive anticoagulation
therapy.34 However, anticoagulant therapy is at least as
beneﬁcial in women as in men with AF.35 Speciﬁc attention is
warranted to promote anticoagulation therapy among women
with AF. Indeed, initial decisions on oral anticoagulant
treatment could be guided by a CHA2DS2-VA score (ie,
excluding the sex category criterion), but the Sc risk
component may modify and possibly increase stroke risk in
women with ≥2 additional stroke risk factors.13
However, some limitations of the study should be noted.
First, the patients in this study were derived from hospitals in
Beijing; thus, more symptomatic or sicker patients were
possibly more likely to be selected. Also, the numbers of
patients and events in our prospective cohort were not
comparable with the other nationwide registries. In addition,
only information about patient characteristics taken at the
baseline was used for the analyses, and hence, the effects of
changes in increasing age and incident comorbidities were not
taken into consideration.36,37 AF categorization in our study
did not differentiate permanent AF from persistent AF.
Because this categorization applies to both male and female
patients, the results are less likely to be impacted by this
limitation. Finally, we lacked information about hormone
replacement therapy, which may have a role in stroke risk;
however, this potential bias is likely to be minimal because
the awareness and use of hormone replacement therapy are
comparatively low in China.38
Conclusions
Crude incidence rates of thromboembolism were higher in
Chinese female patients with AF compared with male patients,
but female sex did not emerge as an independent risk factor
for stroke and systemic embolism on multivariate analysis. In
Chinese AF subjects, initial decisions on oral anticoagulant
treatment guided by a CHA2DS2-VA approach (ie, ignoring the
Sex category [Sc] criterion) may be appropriate.
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Table S1. Associations Between Baseline Factors and Ischemic Stroke/SE. 
Variable 
Univariate Analysis Multivariate Analysis 
HR (95%CI) P value HR (95%CI) P value 
Sex, female 1.24 (0.99-1.54) 0.058 1.09 (0.86-1.39) 0.482 
Age, per year 1.05 (1.04-1.07) <.0001 1.04 (1.02-1.05) <.0001 
BMI>28kg/m2  0.83 (0.60-1.15) 0.265 / / 
SBP>140mmHg 1.42 (1.14-1.78) 0.002 / / 
Pulse pressure>60mmHg 1.31 (1.01-1.69) 0.041 / / 
Heart rate>100bpm   1.01 (0.74-1.38) 0.939 / / 
eGFR<60 mL/min/1.73m2   1.42 (0.92-2.18) 0.110 0.69 (0.43-1.11) 0.129 
Left atrial diameter>40mm   1.57 (1.21-2.04) 0.001 1.45 (1.06-2.00) 0.0225 
Moderate-to-severe mitral 
regurgitation 
1.44 (0.90-2.31) 0.127 1.07 (0.67-1.72) 0.780 
Smoking (any)  0.87 (0.68-1.10) 0.240 / / 
Alcohol use (any)  0.86 (0.67-1.10) 0.220 / / 
Persistent AF    1.15 (0.92-1.44) 0.220 / / 
Medical history     
    Heart failure   1.76 (1.39-2.22) <.0001 1.15 (0.88-1.51) 0.312 
    Hypertension   1.98 (1.50-2.60) <.0001 1.48 (1.07-2.04) 0.0168 
    Diabetes mellitus   1.46 (1.16-1.84) 0.002 1.16 (0.90-1.50) 0.248 
    Thromboembolism 2.51 (1.98-3.17) <.0001 2.03 (1.57-2.64) <.0001 
    Vascular disease  1.24 (0.96-1.59) 0.097 0.86 (0.65-1.14) 0.307 
    Previous bleeding  1.97 (1.35-2.86) <.0001 1.25 (0.81-1.93) 0.308 
    Hyperlipidemia  1.08 (0.85-1.36) 0.540 / / 
Use of Statins 1.04 (0.84-1.30) 0.706 / / 
Use of ACEIs/ARBs  1.19 (0.95-1.48) 0.127 0.86 (0.67-1.10) 0.228 
Completed high school 0.75 (0.57-0.98) 0.032 0.87 (0.66-1.16) 0.344 
Health insurance (any) 1.22 (0.79-1.88) 0.363 / / 
BMI, body mass index; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; ACEIs, 
angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers. 
 
